The Blind Vest

Have you ever wondered what it would be like if the whole world knew your pain? Would you feel exposed or liberated? Would you be embarrassed or relieved? Would others treat you differently? I frankly never gave it any thought until 3 weeks ago when Craig and I took the children to Colorado for their first ski trip.

We enrolled Christiane in a program called Challenge Aspen, where children with special needs are taught to ski. Her instructor, Chloe, had worked with children with all sorts of disabilities and turned out to be a perfect choice for Christiane. While Christiane is not totally blind, her vision is blurry with dark spots; she sees shapes and shadows and struggles to focus on objects up close. Chloe asked me how Christiane would feel about wearing a fluorescent vest that indicated she was visually impaired. At first I felt exposed and uncertain about drawing so much attention to Christiane, but the obvious necessity to alert other skiers that she was skiing with a visual impairment made it an easy decision. So off they went, in matching orange and green vests, with Christiane’s reading “Blind Athlete” and Chloe’s reading “Guide for the Blind.” I followed behind and watched in awe as Christiane began to trust her instructor as she was led down the slope holding on to Chloe’s pole that was extended horizontally in front of her.

Read More

March 2013: Passion is our driver. Strategy is our compass.

Passion is our driver. Strategy is our compass. With your support, Beyond Batten Disease Foundation (BBDF) has developed a dynamic plan to diagnose and prevent juvenile Batten disease while at the same time investing in the most promising research to treat children and families living with the disease. Since the foundation’s inception in August 2008, we have made exciting progress. With help from donors, we have 1) developed an easy and inexpensive test to prevent Batten and hundreds of other rare and devastating diseases, and 2) invested in research projects and strategies that are accelerating progress toward a cure.

Read More

Collaborative CNS Screening Initiative

Collaborative CNS Screening Initiative (CCSI) Aims to Share Knowledge and Speed Drug Discovery.
The Alzheimer’s Drug Discovery Foundation (ADDF), Beyond Batten Disease Foundation (BBDF) and the National Multiple Sclerosis Society today announced a funding collaboration to support the creation of the Collaborative CNS Screening Initiative (CCSI), a central repository of chemical compounds that have shown significant Central Nervous System (CNS) activity.

Download the Press Release »

Nonprofit Funders Unite to Accelerate Fight Against Batten Disease, Granting $1 Million for Research to Develop Treatment and Cure

AUSTIN, TEXAS (February, 2013) The Batten Disease Support and Research Association (BDSRA) and Beyond Batten Disease Foundation (BBDF), working together in close partnership with more than 20 other nonprofits around the world, today announced grants totaling almost $1 million for research to develop treatments and a cure for Batten disease.

Batten disease is a rare and fatal neurodegenerative disorder that strikes infants, children and adults. There is no known treatment or cure. Those born to parents who carry gene mutations for Batten disease are at risk to inherit the condition which can cause vision loss and seizures, progressively impairs cognitive and motor capacities, and ultimately results in death.

Funding for research has been challenging due to the rare nature of the disease. The 2013 grants represent the largest Batten disease research collaboration to date. The new grants will support nine high-value projects at universities and institutes in the United States, Great Britain, Germany, Israel and New Zealand. The goals of these projects include:

Organizations pooling their funds for the nearly $1 million in grants include BDSRA, BBDF, Hope for Bridget, Blake’s Purpose, Our Promise to Nicholas, Fight for Nicholas, Biomarin, LLC, and Noah’s Hope – all based in the United States – along with Germany’s NCL-Stiftung and the United Kingdom’s Batten Disease Family Association. Together these organizations are funding basic discovery to identify drug targets, translate those discoveries into treatment, and prepare for clinical trial success. Expanding, improving and connecting registries will result in the world’s largest, clinically and genetically best characterized set of Batten disease patients. Exploring multiple approaches to identify biomarkers capable of measuring the efficacy of potential drugs for treating Batten disease will ensure clinical trial success.

“We are so proud of the accomplishments of all the organizations and dedicated scientists involved in this unprecedented, international effort to identify and fund research for curing this devastating disease,” said Margie Frazier, PhD, executive director of the BDSRA. “This is a great example of the whole being so much greater than the sum of its parts.”

The world’s leading Batten disease nonprofit organizations are uniting to pool funds and expertise to evaluate grant proposals based on a state-of-the-art scientific merit review process that reflects the highest standards associated with the U.S. National Institutes of Health, the European Research Council and industry-standard drug discovery processes.

“We’ve crossed a major milestone in the fight against Batten disease,” said Craig Benson, founder and CEO of Beyond Batten Disease Foundation. “Through this type of global collaboration, we can take an even more strategic approach and apply both greater rigor and resources to our work, ensuring that the most important research to treat and cure this horrific illness gets funded.”

The newly funded work will be completed at University of Texas Southwestern Medical Center, Yale University, University of Iowa and University of Medicine and Dentistry in the US; Weizmann Institute of Science in Israel; King’s College London in the United Kingdom; University Medical Center Hamburg-Eppendorf in Germany; and Lincoln University in New Zealand.

Other nonprofits joining Batten Disease Support and Research Association and Beyond Batten Disease Foundation in the fight against Batten Disease include: Catherine’s Hope for a Cure, Drew’s Hope, Hayden’s Hope, Luke and Rachel Batten Foundation, Mary Payton’s Miracle Foundation, Melissa Froio Foundation, Partnering for Cures and Taylor’s Tale in the US; Jasper Against Batten in the US and Netherlands; Beat Batten! in the Netherlands; Bee for Batten’s in Ireland; ContactPuntNCL in Belgium; NCL-Gruppe Deutschland in Germany; and Norsk Spielmeyer-Vogt Forening in Norway.

About The Batten Disease Support and Research Association

The Batten Disease Support and Research Association is the major support and research organization in North America for families who have children with the disease. Founded in 1987, the association promotes and funds research nationally and internationally, provides family services and advocacy, fosters awareness and education with the scientific, medical and caregiving community, and coordinates networks for diagnosis, medical referrals, genetic testing, and counseling. The first research grant from BDSRA was awarded in 1992 and, since then, more than $6 million in funding has been awarded. BDSRA is the largest source of private funding for family support and research into the disease. For more information, visit www.bdsra.org.

About Beyond Batten Disease Foundation

Beyond Batten Disease Foundation works to cure and prevent juvenile Batten disease, a rare, inherited neurological disorder that strikes young children; first causing vision loss and seizures, then cognitive and motor impairment, and ultimately, death by the late teens or 20s. The foundation raises funds for research, and is leading the development of an easy, inexpensive, groundbreaking blood test to detect gene mutations that cause Batten disease as well as 600 other rare, serious and often fatal, childhood ailments. For more information, visit www.beyondbatten.org.

# # #

Contact:
Danielle M Kerkovich, PhD
Scientific Officer | Batten Disease Support and Research Association
Principal Scientist | Beyond Batten Disease Foundation
info@beyondbatten.org
202-812-6462
www.bdsra.org
www.beyondbatten.org

Faster DNA Testing Helps Diagnose Disease in NICU Babies

by Alice Park on healthland.time.com

Fifty hours. That’s how long it now takes to decode and interpret a newborn baby’s genome — an undertaking that used to take weeks, or even months. And those two days can mean the difference between life and death for a critically ill infant.

In a paper published in the journal Science Translational Medicine, researchers led by Stephen Kingsmore, director of the Center for Pediatric Genomic Medicine at Children’s Mercy Hospital, describe a new genetic test that can rapidly screen the DNA of babies in the neonatal intensive care unit (NICU) for about 3,500 diseases known to be linked to single-gene mutations. Of these, doctors can treat about 500.

Up to a third of babies admitted to the NICU have a genetic disease. But many newborns are not diagnosed properly and may therefore miss the opportunity for a potentially life-saving therapy. Many of the symptoms of such genetic diseases are both general and shared by many different conditions, which makes them difficult to diagnose; what’s more, many of the genetic conditions in question are rare, so most physicians, even NICU specialists, may not be familiar them or unable to recognize their symptoms. Currently used genetic tests are also too expensive and time-consuming to be clinically useful; because the tests can take weeks, or sometimes months, most NICU babies will have either gone home or died by the time the results are ready.

So Kingsmore and his colleagues collaborated with Illumina, a manufacturer of gene-sequencing machines, to shorten the time it takes to both decode an entire genome and generate a clinically useful analysis of that sequencing. Thanks to recent advances in the ability to break up and re-knit DNA, the company was able to sequence the 3 billion base pairs of the genome in just 27 hours — down from weeks.

But decoding a genome is only half of the challenge. Words in a book don’t make sense unless they are put together in a grammatically sensible way, and similarly, DNA is meaningless unless it’s analyzed in the context of genes, which in turn are connected to human functions or conditions. So for two years, Kingsmore’s team worked on special software designed to help doctors use genetic information to make accurate diagnoses and guide ill babies to the right treatment.

The software simplifies and standardizes the often complex process of diagnosis, by allowing doctors to click on the symptoms they see in newborns; the program then puts together a list of the genes that might be most likely to be at fault. Doctors can then compare these genetic suspects to the newborn’s sequenced genome to see if any of the same genes are mutated; if they are, they can pinpoint a diagnosis.

 “There is a phenomenal need for more accurate and faster diagnosis in the NICU,” says Kingsmore, adding that “this is a setting where we know that giving treatments is one of the most effective things we can do in medicine from the cost standpoint, since these patients have 65 to 70 years of life to live out.”

Of the 4 million babies born in the U.S. each year, about 1 in 20 are admitted to the NICU for potentially life-threatening reasons, and about 30% of those are for inherited genetic diseases. Accurately diagnosing these babies can help them get effective treatments that can improve their quality of life and in many cases save them from an early death.

Using the combination of the prototype Illumina sequencer and the new software, Kingsmore and his team have sequenced 15 babies’ genomes as part of their study, and have seen how powerful the screening can be. In the case of Pompe disease, for example, in which a genetic abnormality leaves babies deficient in an enzyme that breaks down glycogen (a form of sugar the body uses for energy), the genetic sequencing can pick up the mutation and alert the doctor to begin giving the baby the enzyme, which drug companies make as a therapy. The treatment can keep infants off ventilators and offset some of the heart and muscle damage that Pompe disease causes.

Newborns with Menkes disease can also benefit from the screening; their bodies cannot break down copper, so they need injections of the mineral. Without a genetic screen to confirm the deficiency, however, doctors wouldn’t know to treat them. And giving excess copper to babies who aren’t deficient can be dangerous, leading to copper poisoning, with diarrhea, convulsions and liver failure.

Timing is critical in the NICU, and Kingsmore says the ability to get an accurate diagnosis in two days can lead to dramatic improvements in survival and quality of life for many NICU babies. For now, the screening is only available on an experimental basis, as part of ongoing research, but he anticipates that such genetic testing will become ubiquitous as the price of sequencing continues to drop. Next year, he’s planning to offer the testing to other hospitals that will courier DNA samples to Children’s Mercy. “We expect better outcomes and broader benefits to follow from doing this,” he says. And hopefully many more lives saved.

http://healthland.time.com/2012/10/04/good-news-for-nicu-babies-faster-dna-testing-for-more-accurate-diagnoses/

Beyond the Valley of Death: A Strategic Path Toward a Cure for Batten disease

Beyond Batten Disease Foundation is spearheading a unique, cohesive strategy that incorporates independent scientific resources and collaborations with related funding organizations to drive research into Batten Disease. Watch the following video to see how Beyond Batten Disease Foundation is working with academia, the pharmaceutical industry, and government agencies to cross the “Valley of Death” between initial scientific discoveries and meaningful progress toward treatments and cures.

Featured Fundraiser


On Sunday October 21st, 25 girls gathered in Grace and Brynley May’s front yard to show support for one of their school mates. Each girl baked beautifully decorated trays of delicious cookies, cupcakes and brownies and delivered them to tables lining the front yard. Fourth grade girls welcomed neighbors along the sidewalk and flagged down passing cars with homemade signs until every baked goodie was sold.

The girls awarded Beyond Batten Disease Foundation $1,000 with their loving and supportive efforts to help a friend. Thank you so much to all who participated, and especially Grace and Brynley for organizing the bake sale and offering their home.

A Mother’s Story

With the holidays approaching, the children and I have decided to decorate our front yard with characters from our favorite Christmas story…….Dr. Seuss’ How the Grinch Stole Christmas. Twelve years ago, my brother, John, made a Grinch who sat on the front porch at Christmas, and I remember all of the children being fixated on every detail, fascinated with his yellow eyes, bright green skin, and long fingernails. Every wrinkle of his face was animated with a grin that held the awful thought of his plot to end Christmas by stealing it away from the Whos. Every child imagined what it would be like to wake up with no presents or toys, and the Grinch would finally be satisfied that he had put an end to the noise and commotion of Christmas.

Read More
1 19 20 21 22 23 29